EBS — Emergent BioSolutions Inc.
Is EBS overbought or oversold? Here is the current MarketMoodz read.
Emergent BioSolutions Inc. (EBS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $5.81. The rating moved from Strong Oversold to Oversold on November 7, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$5.81
- Last changeMoved from Strong Oversold to Oversold on November 7, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
See all oversold Healthcare stocks →
AI analysis
Emergent BioSolutions faces near-term downside risks driven by concentrated government-dependent revenues, a track record of manufacturing and compliance issues, and a constrained commercial pipeline. The company’s cash flow profile is lumpy and sensitive to contract timing, creating potential liquidity and dilution pressure. Recovery scenarios require clear, sustained remediation, new multi-year contract awards, or strategic portfolio moves. Absent those catalysts, downside remains more likely over the coming weeks as investor preference favors larger, less operationally risky healthcare names.
Key factors
- Highly concentrated revenue mix with significant reliance on government contracts and biodefense programs, producing lumpiness and sensitivity to procurement/timing
- History of manufacturing quality and compliance issues that elevate regulatory and remediation costs and can limit contract wins
- Weak share price and market capitalization reflecting investor concerns and limited liquidity for a recovery narrative
- Limited diversified commercial portfolio and pipeline compared with larger biotech/pharma peers, constraining organic growth potential
- Balance sheet pressure risk from episodic cash flow; potential need for dilutive financing if contract timing slips or unexpected liabilities arise
- Defensive sector flows favoring large-cap pharma rather than smaller, higher-risk biopharma reduces relative investor demand
Risks
- Loss, delay, or non-renewal of material government contracts or reduced biodefense spending
- Further regulatory actions, inspections or plant shutdowns tied to manufacturing quality that would impede revenue recognition
- Large litigation or settlement costs related to past manufacturing failures or product issues
- Equity dilution from future financing or convertible instruments if cash generation is insufficient
- Positive catalyst risk: successful remediation, new multi-year government agreements, or asset sale that could materially boost shares
- Broader market risk — risk-off environment or reduced defense/healthcare discretionary funding could lower bids
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for EBS — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.